>
STADA Arzneimittel AG logo

SAZ - STADA Arzneimittel AG Share Price

€86 0.0  0.0%

Last Trade - 02/12/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £2.62bn
Position in Universe th / 1051
Bullish
Bearish
Unlock SAZ Revenue
Momentum
Relative Strength (%)
1m +1.83%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2,115 2,139 2,314 2,331 2,609 3,010 2,832 2,962 +7.3%
+0.8 +7.8 +24.9 +34.9 -31.3 +9.4 -2.95 +6.47
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, STADAArzneimittel AG revenues increased 15% to EUR3.01B. Netincome decreased 45% to EUR167.3M. Revenues reflect BrandedProducts segment increase of 27% to EUR1.37B, Genericssegment increase of 7% to EUR1.65B, Other Countries segmentincrease of 22% to EUR1.09B, Russia segment increase of 52%to EUR433M, United Kingdom segment increase of 11% toEUR343.8M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SAZ Revenue Unlock SAZ Revenue

Net Income

SAZ Net Income Unlock SAZ Revenue

Normalised EPS

SAZ Normalised EPS Unlock SAZ Revenue

PE Ratio Range

SAZ PE Ratio Range Unlock SAZ Revenue

Dividend Yield Range

SAZ Dividend Yield Range Unlock SAZ Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SAZ EPS Forecasts Unlock SAZ Revenue
Profile Summary

STADA Arzneimittel AG (STADA) is a global pharmaceutical company that focuses on multisource products. Its product portfolio is concentrated on active ingredients, which are free of patent restriction. It focuses on three core business segments: Generics offers drugs in the multisource product category, made from readily available, off-patent active ingredients; Brand-Name Products focuses on multisource products that are accessible without active ingredient research and are principally offered to the public in the non-prescription and self-medication product sectors, while Special Pharmaceuticals focuses on products with specific market entry barriers or specialized sales structures, including oncological drugs. STADA generics are sold by numerous subsidiaries in the respective national markets.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since August 24, 2004
No. of Shareholders: n/a
No. of Employees: 12,310
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Dusseldorf Stock Exchange
Shares in Issue 62,258,167
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SAZ Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SAZ
Upcoming Events for SAZ
Frequently Asked Questions for STADA Arzneimittel AG
What is the STADA Arzneimittel AG share price?

As of 02/12/19, shares in STADA Arzneimittel AG are trading at €86, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the STADA Arzneimittel AG share price performed this year?

Shares in STADA Arzneimittel AG are currently trading at €86 and the price has moved by 7.23% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the STADA Arzneimittel AG price has moved by -16.66% over the past year.

What are the analyst and broker recommendations for STADA Arzneimittel AG?

Of the analysts with advisory recommendations for STADA Arzneimittel AG, there are there are currently 0 "buy" , 1 "hold" and 1 "sell" recommendations. The overall consensus recommendation for STADA Arzneimittel AG is Sell. You can view the full broker recommendation list by unlocking its StockReport.

When will STADA Arzneimittel AG next release its financial results?

STADA Arzneimittel AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the STADA Arzneimittel AG dividend yield?

STADA Arzneimittel AG does not currently pay a dividend.

Does STADA Arzneimittel AG pay a dividend?

STADA Arzneimittel AG does not currently pay a dividend.

When does STADA Arzneimittel AG next pay dividends?

STADA Arzneimittel AG does not currently pay a dividend.

How do I buy STADA Arzneimittel AG shares?

To buy shares in STADA Arzneimittel AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of STADA Arzneimittel AG?

Shares in STADA Arzneimittel AG are currently trading at €86, giving the company a market capitalisation of £n/a.

Where are STADA Arzneimittel AG shares listed? Where are STADA Arzneimittel AG shares listed?

Here are the trading details for STADA Arzneimittel AG:

Country of listing: Germany
Exchange: DUS
Ticker Symbol: SAZ
What kind of share is STADA Arzneimittel AG?

We were not able to load our ranking data for STADA Arzneimittel AG

Is there a STADA Arzneimittel AG share price forecast 2021?

We were not able to load any forecast data for STADA Arzneimittel AG.

How can I tell whether the STADA Arzneimittel AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like STADA Arzneimittel AG. Over the past six months, the relative strength of its shares against the market has been -11.3%. At the current price of €86, shares in STADA Arzneimittel AG are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the STADA Arzneimittel AG PE Ratio?

We were not able to find PE ratio data for STADA Arzneimittel AG.

Who are the key directors of STADA Arzneimittel AG?

STADA Arzneimittel AG's management team is headed by:

Eric Cornut - IND
Guenter Au - CSU
Jan-Nicolas Garbe - SUB
Benjamin Kunstler - SUB
Bruno Schick - SUB
Peter Goldschmidt - CMG
Miguel Fernandez - CTO
Wolfgang Ollig - CFO
Markus Damm - VSU
Klaus Scheja - SUB
Who are the major shareholders of STADA Arzneimittel AG?

Here are the top five shareholders of STADA Arzneimittel AG based on the size of their shareholding:

BN & Partners Deutschland AG Investment Advisor
Percentage owned: 0.26% (165k shares)
ProfitlichSchmidlin Fonds UI Mutual Fund
Percentage owned: 0.19% (119k shares)
KBC Fund Management Limited Investment Advisor/Hedge Fund
Percentage owned: 0.08% (49.9k shares)
Alternative Fixed Income Fund Mutual Fund
Percentage owned: 0.07% (46.0k shares)
Signal Iduna Asset Management GmbH Investment Advisor
Percentage owned: 0.02% (15.2k shares)
Similar to SAZ
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.